Opinion

Video

Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Daniel Canter, MD, on the potential impact of 89Zr-girentuximab in kidney cancer
      Daniel Canter, MD, on the potential impact of 89Zr-girentuximab in kidney cancer
      Study explores treatment trends in patients with localized kidney tumors
      Study explores treatment trends in patients with localized kidney tumors
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Related Content
      Bevacizumab plus erlotinib is highly active in HLRCC-associated papillary renal cell carcinoma
      September 18th 2025

      Bevacizumab plus erlotinib is highly active in HLRCC-associated papillary renal cell carcinoma

      Hannah Clarke
      First Assist: The Historical Context of Advanced Kidney Cancer, with Eric A. Singer, MD
      September 18th 2025

      First Assist: The Historical Context of Advanced Kidney Cancer, with Eric A. Singer, MD

      Taylor Goodstein, MD
      Pembrolizumab plus axitinib shows sustained benefit vs sunitinib in ccRCC
      September 18th 2025

      Pembrolizumab plus axitinib shows sustained benefit vs sunitinib in ccRCC

      Hannah Clarke
      Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC
      September 18th 2025

      Metastasis-directed radiotherapy without systemic therapy yields promising outcomes in oligometastatic ccRCC

      Hannah Clarke
      What urologists can expect in Q3 of 2025
      September 18th 2025

      What urologists can expect in Q3 of 2025

      Benjamin P. Saylor Hannah Clarke
      3d rendered medically accurate illustration of kidney cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      September 18th 2025

      Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

      Hannah Clarke
      © 2025 MJH Life Sciences

      All rights reserved.